Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211, Geneva, Switzerland.
Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Comput Biol Med. 2021 May;132:104304. doi: 10.1016/j.compbiomed.2021.104304. Epub 2021 Mar 3.
To develop prognostic models for survival (alive or deceased status) prediction of COVID-19 patients using clinical data (demographics and history, laboratory tests, visual scoring by radiologists) and lung/lesion radiomic features extracted from chest CT images.
Overall, 152 patients were enrolled in this study protocol. These were divided into 106 training/validation and 46 test datasets (untouched during training), respectively. Radiomic features were extracted from the segmented lungs and infectious lesions separately from chest CT images. Clinical data, including patients' history and demographics, laboratory tests and radiological scores were also collected. Univariate analysis was first performed (q-value reported after false discovery rate (FDR) correction) to determine the most predictive features among all imaging and clinical data. Prognostic modeling of survival was performed using radiomic features and clinical data, separately or in combination. Maximum relevance minimum redundancy (MRMR) and XGBoost were used for feature selection and classification. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC), sensitivity, specificity, and accuracy were used to assess the prognostic performance of the models on the test datasets.
For clinical data, cancer comorbidity (q-value < 0.01), consciousness level (q-value < 0.05) and radiological score involved zone (q-value < 0.02) were found to have high correlated features with outcome. Oxygen saturation (AUC = 0.73, q-value < 0.01) and Blood Urea Nitrogen (AUC = 0.72, q-value = 0.72) were identified as high clinical features. For lung radiomic features, SAHGLE (AUC = 0.70) and HGLZE (AUC = 0.67) from GLSZM were identified as most prognostic features. Amongst lesion radiomic features, RLNU from GLRLM (AUC = 0.73), HGLZE from GLSZM (AUC = 0.73) had the highest performance. In multivariate analysis, combining lung, lesion and clinical features was determined to provide the most accurate prognostic model (AUC = 0.95 ± 0.029 (95%CI: 0.95-0.96), accuracy = 0.88 ± 0.046 (95% CI: 0.88-0.89), sensitivity = 0.88 ± 0.066 (95% CI = 0.87-0.9) and specificity = 0.89 ± 0.07 (95% CI = 0.87-0.9)).
Combination of radiomic features and clinical data can effectively predict outcome in COVID-19 patients. The developed model has significant potential for improved management of COVID-19 patients.
使用临床数据(人口统计学和病史、实验室检查、放射科医生的视觉评分)和从胸部 CT 图像中提取的肺部/病变放射组学特征,为 COVID-19 患者的生存(存活或死亡状态)预测开发预后模型。
总共纳入了 152 名符合本研究方案的患者。他们分别分为 106 名训练/验证和 46 名测试数据集(在训练过程中未触及)。从胸部 CT 图像中分别提取肺部和感染性病变的放射组学特征。还收集了临床数据,包括患者的病史和人口统计学、实验室检查和放射学评分。首先进行单变量分析(报告错误发现率 (FDR) 校正后的 q 值),以确定所有成像和临床数据中最具预测性的特征。分别或组合使用放射组学特征和临床数据进行生存预后建模。最大相关性最小冗余 (MRMR) 和 XGBoost 用于特征选择和分类。接收器操作特征 (ROC) 曲线和 ROC 曲线下面积 (AUC)、敏感性、特异性和准确性用于评估模型在测试数据集上的预后性能。
对于临床数据,发现癌症合并症(q 值<0.01)、意识水平(q 值<0.05)和放射学评分涉及区域(q 值<0.02)与结局有高度相关特征。氧饱和度(AUC=0.73,q 值<0.01)和血尿素氮(AUC=0.72,q 值=0.72)被确定为高临床特征。对于肺部放射组学特征,GLSZM 中的 SAHGLE(AUC=0.70)和 HGLZE(AUC=0.70)被确定为最具预后的特征。在病变放射组学特征中,GLRLM 中的 RLNU(AUC=0.73)和 GLSZM 中的 HGLZE(AUC=0.73)表现最佳。在多变量分析中,确定结合肺部、病变和临床特征可以提供最准确的预后模型(AUC=0.95±0.029(95%CI:0.95-0.96),准确性=0.88±0.046(95%CI:0.88-0.89),敏感性=0.88±0.066(95%CI:0.87-0.9)和特异性=0.89±0.07(95%CI:0.87-0.9))。
放射组学特征和临床数据的组合可以有效预测 COVID-19 患者的结局。所开发的模型对改善 COVID-19 患者的管理具有重要意义。